Clinical Trial Update: Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing how hepatic impairment, including cirrhosis, influences the pharmacokinetics and safety of VIR-2218 and VIR-3434. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis

Drugs mentioned

• VIR-2218
• VIR-3434

Snippet

Sponsor: Vir Biotechnology, Inc. | Conditions: Hepatic Impairment, Cirrhosis | Phase 1 | Status: RECRUITING